EMA Authorised: Actos (pioglitazone hydrochloride) — CHEPLAPHARM Arzneimittel GmbH

View source ↗

Summary

EMA authorises Actos (pioglitazone hydrochloride) for diabetes mellitus type 2 through CHEPLAPHARM Arzneimittel GmbH.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Actos (Pioglitazone)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: CHEPLAPHARM Arzneimittel GmbH. Decision date: 11/08/2023